Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027

Loading news article.

Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027 | WAPE

Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027

Article summary

Related companies

Comments —